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ABSTRACT 
Etodolac is an indole acetic acid derivative with half-life of 4 to 7hrs. It is used for the 
treatment of Rheumatoid arthritis. Wheneverused orally, it has many systemic side effects, 
so it is not preferred orally. In present study four niosomes formulations of Etodolac were 
successfully developed by modified ether injection technique using different nonionic 
surfactant i.e. Span 20, Span 40, Tween 20, Tween 40 and cholesterol. Formulations were 
evaluated for different parameters like particle size, entrapment efficiency, in-vitro release, 
stability studies. 
Keywords: Cholesterol, modified ether injection method, Etodolac, in-vitro release, 
niosomes, stability studies surfactants. 
INTRODUCTION 
The main aim of any novel drug delivery system is to provide a therapeuticamount of drug to 
reach to the desired site in the body and then maintain the required drug concentration to produce 
therapeutic effect
1
. Niosome is a class of molecular cluster formed by self-association of non-
ionic surfactants in an aqueous phase
2
.  Niosomes are non-ionic surfactant based multilamellar or 
unilamellar vesicles in which an aqueous solution of solute is enclosed by a membrane. 
Niosomes are promising vehicle for drug delivery and being non-ionic; and Niosomes are 
biodegradable, biocompatible non-immunogenic and exhibit flexibility in their structural 
characterization. 
The first niosome formulations were developed and patented by L’Oreal in 19755. Niosomes 
serve as drug depot in the body which releases the drug in a controlledmanner through its bilayer 
providing sustained release of the enclosed drug
3
.  
Etodolac is a nonsteroidal anti-inflammatory drug of COX-2 inhibitor class used for 
osteoarthritis, rheumatoid arthritis, gout, rheumatoid arthritis and traumatic injury. It produces 
therapeutic effects by inhibition of prostaglandin synthesis
4
. 
Due to extensive first pass metabolism it has low bioavailability. Since its terminal half life is   
4-7 hrs and hence frequent dosing is required. Frequent oral use ofEtodolac leads to serious 
gastrointestinal disturbance such as ulcer, stomach, or intestinal bleeding and chest pain which 
may be harmful. Gastrointestinal side effects produced by NSAIDs are either due to direct 
contact or indirect effect of the drug on the gastrointestinal mucosa
5
.Etodolac have been 
formulated and evaluated on different parameters to avoid all problems and to improve its oral 
bioavailability
6
. 
MATERIALS AND METHODS 
 Etodolac was received as gift sample from Neimeth International Pharmaceuticals, Span 20, 
Span 40, Tween 20, Tween 40 and Cholesterol (Mopson Pharmaceutical Ltd).  
Formulation development by modified ether injection technique 
Niosomes containing Etodolac were prepared by modified ether injection technique using 
nonionic surfactant and cholesterol at different concentrations (Table 1).  
For it, Cholesterol and surfactant were dissolved in 6 ml diethyl ether mixed with 2ml methanol 
containing weighed quantity of Etodolac. The resulting solution was introduced by means of 
micro syringe into 20ml of solution of phosphate buffer (pH 7.4). The solutionwas stirred 
continuously on magnetic stirrer and temperature was maintained at 60-65ºC. While the lipid 
solution was injected slowly into aqueous phase, it causes vaporization of ether, resulting in 
spontaneous vesiculation and formation of niosomes
7
. 
 Table 1: Compositions of the Etodolac niosomes formulations 
S.N. Formulation 
code 
Surfactant Drug: 
surfactant: 
cholesterol 
(mg) 
1. N1 Tween 20 100:100:100 
2. N2 Tween 40 100:200:100 
3. N3 Span 20 100:100:100 
4. N4 Span 40 100:200:100 
 
EVALUATION OF FORMULATIONS 
1. Particle size 
Vesicle size determination was carried out by means of an optical microscopy with a calibrated 
eyepiece micrometer. About 200 niosomes were measuredindividually, average was taken, and 
their size range, mean diameter were calculated
8
. 
2.  Entrapment efficiency 
  The percentage entrapment efficiency of the vesicles was determined by freeze thawing  
centrifugation technique. Niosomal suspension was filled in drop tubes and stored at -20ºC in a 
refrigerator for 24 hours. The niosomal suspension was centrifuged at 1500 X G rpm for 30 
minute. Supernatant containing unentrapped drug was withdrawn and diluted with water 
methanol mixture, then measured UV spectrophotometrically at 278nm againstwater methanol 
mixture as standard
9
.  
Entrapment efficiency was calculated by using following equation:- 
      
                                    
                                                                      
Table 2: Properties of Etodolac niosomes 
S.N. Formulation 
Code 
Average mean 
diameter of non 
sonicated 
niosomes (µ m)
 a
 
% Entrapment 
efficacy
 a
 
Viscosity 
(Centipoise) 
1.  N1 2.37±0.08 66.52±0.22 2.421 
2.  N2 2.41±0.14 68.21±0.23 2.318 
3.  N3 2.46±0.09 73.40±0.12 2.329 
4.  N4 2.28±0.11 78.32±0.13 3.388 
a
 Average  SD of three determination  
 
3.  In-vitro drug release 
The in-vitro permeation of Etodolac from niosomal formulation was studied using locally 
fabricated diffusion cell. The in-vitro diffusion of the drug through egg membrane was 
performed
10
. It was clamped carefully to one end of the hollow glass tube of 17mm (area 
2.011cm²) (dialysis cell) this acted as donor compartment. 100ml of phosphate buffer saline PBS 
7.4 was taken in a beaker which was used as a receptor compartment. The known quantity was 
spread uniformly on the membrane. The donor compartment was kept in contact with the 
receptor compartment and the temperature was maintained at 37±0.1
0
C. The solutions of the 
receptor side were stirred by externally driven Teflon-coated magnetic bars.  
 At predetermined time intervals, sample was withdrawn and replaced by 4ml of PBS. The drug 
concentrations in the aliquot were determined at 278nm against appropriate blank. Drug release 
data was normalized by converting the drug concentrations in solution to a percentage of 
cumulative drug release and was shown graphically. 
 
Fig 1:  Percentage of drug released from Etodolac niosomes 
 
4.   Stability study 
Stability studies carried out by storing the prepared niosomes of Etodolac at various temperature 
conditions like refrigeration on (2-8
0
C) room temperature (25±0.5
0
C) and elevated temperature 
(45±0.5
0
C) for a period of 12 weeks. Drug content and variation in the average vesicle diameter 
were periodically monitored
11
. ICH (International Conference on Harmonisation) guidelines 
suggests stability studies for dry niosomes powder meant for reconstitutionshould be studied for 
accelerated stability at 75% relative humidity as per international climatic zones and climatic 
conditions. 
 
Fig 2: Stability study of Etodolac niosomes of batch N4 at different temperature 
 
RESULTS AND DISCUSSION 
A successful attempt was made to formulate four formulations of Etodolac niosomes 
formulations by modified ether injection technique using nonionicsurfactant and cholesterol at 
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 different concentrations. The pure drug shows sensitivity to light and moisture. Therefore 
formulating it into niosomes can solve this problem to a large extent.  
The mean particle diameter of the Etodolac was between 2.28-2.46 µm for all twelve 
formulations. Particles of all formulations were smooth, oval and discrete. Niosomes 
formulations of batch N3 shows maximum mean particle diameter i.e. 2.46 µm. The entrapment 
efficiency of the niosomes was between 66.52-78.32%. Theentrapment efficiency was found to 
be higher with the batch N4 (78.32%), which may have an optimum surfactant cholesterol ratio 
to provide a high entrapment of Etodolac. 
The in-vitro permeation of Etodolac from niosomal formulation was studied using locally 
fabricated diffusion cell. The cumulative percent drug release after 10 hrs of the Etodolac 
niosomes in between 40.59-78.55%. 68.5% for N1, 50.49% for N2, 40.59 for N3 and 78.55 for 
N4. The formulation containing tween showed less drug releasecompared with the preparation 
containing span. This may be due to the larger size of the vesicles and less lipophilic nature of 
the Tween, which makes it more difficult for these vesicles to penetrate or fuse with skin 
whereas, the inclusion of span which is more lipophilic than tween further  
increased the lipophilicity of the drug leading to better penetration. Rapid drug leakage was 
observed during the initial phase. However, after that a slow release occurred. This could be 
because the drug is mainly incorporated between the fatty acid chains in the lipidbilayer of 
niosomal vesicles which leads to rapid ionization and release upon dispersing niosomes in large 
buffer (pH 7.4) volumes until reaching equilibrium. 
Stability studies revealed that the niosomes kept at room temperature (~25°C) and 40°-75% RH 
showed the maximum stability. The values of drug content and in-vitro studies were close to that 
of the initial data with only slight variations suggesting that it has an acceptable shelf life. It 
should be stored in a cool, dry place.  Niosomes formulations of Etodolac of batch N4 shows 
good stability at refrigeration and room temperature in comparison to other.   
CONCLUSION 
At present scenario, many researchers are working for transporting the drug molecules to the 
desired site in the biological systems. The role of the drug delivery system is not only limited to 
a drug package just meant for convenience and administration but to bring a requiredchange in 
therapeutic efficacy and safety by carrying the drug molecules to the desired site in the most 
convenient manner. 
In present study four Etodolac niosomes formulations were successfully developed by using 
different surfactants i.e. Span 20, Span 40, Tween 20, Tween 40 by modified ether injection 
method. Accelerated stability studies for 12 weeks revealed that the  Etodolac niosomes 
formulations of batch N4 were stable at up to 450C. The stability study  
of the optimized formulation showed satisfactory 
characteristics without being drastically influenced. Based on particlesize morphology, in-vitro 
release and stability studies, it can be concluded that formulation N4 was an optimum 
formulation. 
However, future experiments should explore the suitability of niosomes with wide variety of 
drugs having designed drawbacks for improved and effective intendedtherapy. So, that niosomes 
are represented as promising drug carriers and promising drug deliverymodule. 
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